The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection
Journal of Pancreatology · 2020-12 · 3 (4) · 167-172
DOI: 10.1097/jp9.0000000000000058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pancreatology, 2020-12. Verfasst von Suizhi Gao und 7 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To investigate the effect of long-acting octreotide as adjuvant therapy in the prevention of tumor recurrence in patients with grade 2 pancreatic neuroendocrine tumors (pNETs) after radical resection.
Methods
The postoperative follow-up data of 130 patients with resectable G2 pNET treated in the Changhai Hospital from 2008 to 2018 were retrospectively analyzed: 59 patients received long-acting octreotide as adjuvant therapy for 6 to 12 months (Oct group) and 71 patients received active follow-up (control group), both of which began after the radical resection, with the primary observation endpoint of disease-free survival (DFS) and the secondary study endpoint of overall survival.
Results
The median age of the patients in the Oct group and control group was 52 and 54 years, respectively. There were 28 male cases (47.5%) and 33 male cases (46.5%) in the 2 groups. The median maximum tumor diameter was 3.5 and 3.0 cm, respectively; lymph node metastasis was positive in 13 cases (22.0%) and 9 cases (12.7%); there was peripancreatic nerve invasion in 11 cases (18.6%) and 6 cases (8.5%). Survival analysis revealed that there were significant differences in 2-year DFS% (98.3% vs 88.7%, P = .0371) and 3-year DFS% (96.6% vs 85.9%, P = .0498) between the Oct group and control group. Long-acting octreotide treatment was found to reduce the risk of 3-year recurrence of G2 pNET after radical resection (HR = 0.2, P = .044) with the application of inverse-probability-of-treatment weighted to balance the limited data bias.
Conclusion
Using long-acting octreotide as adjuvant therapy for G2 pNET patients after radical surgery may improve the rate of 3y-DFS, but the benefit needs to be confirmed in a well-designed random control clinical trial.
Zitieren
APA
Gao, S., Shi, X., Ma, H., Wang, H., Li, B., Song, B., Guo, S., & Jin, G. (2020). The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection. Journal of Pancreatology, 3(4), 167-172. https://doi.org/10.1097/jp9.0000000000000058
Vancouver
Gao S, Shi X, Ma H, Wang H, Li B, Song B, et al. The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection. Journal of Pancreatology. 2020;3(4):167-172. doi:10.1097/jp9.0000000000000058
BibTeX
@article{Gao2020,
author = {Gao, Suizhi and Shi, Xiaohan and Ma, Hongyun and Wang, Huan and Li, Bo and Song, Bin and Guo, Shiwei and Jin, Gang},
title = {The effect of using long-acting octreotide as adjuvant therapy for patients with grade 2 pancreatic neuroendocrine tumors after radical resection},
journal = {Journal of Pancreatology},
year = {2020},
volume = {3},
number = {4},
pages = {167--172},
doi = {10.1097/jp9.0000000000000058}
}
EUVIMED